Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta-Amyloid peptide decreases membrane fluidity

W E Müller1, S Koch, A Eckert

  • 1Department of Psychopharmacology, Central Institute of Mental Health, Mannheim, Germany.

Brain Research
|March 13, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal characterization of inflammatory plasma protein signatures in ECT response.

Journal of affective disorders·2025
Same author

Incidence and presentation of new-onset type 1 diabetes in children and adolescents from Germany during the COVID-19 pandemic 2020 and 2021: Current data from the DPV Registry.

Diabetes research and clinical practice·2023
Same author

MMW Fortschritte der Medizin·2020
Same author

Repetitive enhancement of serum BDNF subsequent to continuation ECT.

Acta psychiatrica Scandinavica·2019
Same author

Genetic ablation of the p66<sup>Shc</sup> adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease.

Molecular psychiatry·2016
Same author

Comparison of Conservative and Surgical Therapy Concepts for Synechia of the Labia in Pre-Pubertal Girls.

Geburtshilfe und Frauenheilkunde·2016

Beta-amyloid peptide-25-35 (beta A25-35) reduces brain membrane fluidity in mice and rats. This effect on membrane properties may contribute to beta-amyloid

Area of Science:

  • Neuroscience
  • Biochemistry
  • Cell Biology

Background:

  • Beta-amyloid peptides are implicated in neurodegenerative diseases.
  • Alterations in cell membrane properties are associated with neurological dysfunction.

Purpose of the Study:

  • To investigate the effect of beta-amyloid peptide-25-35 (beta A25-35) on cell membrane fluidity.
  • To determine if this effect is concentration-dependent and specific to beta A25-35.

Main Methods:

  • Incubation of mouse brain membranes and rat cell membranes (cortex, hippocampus, striatum, cerebellum) with varying concentrations of beta A25-35.
  • Measurement of membrane fluidity using biophysical techniques.
  • Comparison with beta-amyloid peptide(1-40) and scrambled beta A25-35.

Related Experiment Videos

Main Results:

  • Beta A25-35 decreased membrane fluidity in mouse brains and rat lymphocytes, cortex, hippocampus, and striatum in a concentration-dependent manner.
  • Significant effects were observed starting at 100 nmol/L beta A25-35.
  • Beta-amyloid peptide(1-40) showed similar activity, while scrambled beta A25-35 had no effect.

Conclusions:

  • Beta-amyloid peptides, specifically beta A25-35, directly impact cell membrane fluidity.
  • These changes in membrane properties may underlie beta-amyloid's neurotoxic effects and influence cellular calcium signaling.
  • The findings highlight the importance of membrane interactions in beta-amyloid's biological activity.